← FDA DRUG APPROVALS

FDA ANDA · ANDA089408

POLOCAINE-MPF

mepivacaine hydrochloride

Sponsor: FRESENIUS KABI USA

APPLICATION
ANDA089408
TYPE
ANDA
ORIGINAL APPROVAL
1986-12-01
LATEST ACTION
2025-01-29
ROUTE
EPIDURAL, INFILTRATION, INJECTION
DOSAGE FORM
INJECTABLE
MARKETING STATUS
Prescription

Products

POLOCAINE-MPFPrescription
MEPIVACAINE HYDROCHLORIDE 1.5% · INJECTABLE · INJECTION

Approval history

2025-01-29Labeling · Supplement 26 · standardAP
2025-01-29Labeling · Supplement 21 · standardAP
2010-06-15Labeling · Supplement 15AP
2002-05-24Labeling · Supplement 13AP
2002-03-08Manufacturing (CMC) · Supplement 10AP
2001-12-10Labeling · Supplement 12AP
2001-03-30Manufacturing (CMC) · Supplement 9AP
1998-09-29Manufacturing (CMC) · Supplement 7AP
1996-05-31Manufacturing (CMC) · Supplement 6AP
1994-12-27Manufacturing (CMC) · Supplement 5AP
1992-09-18Manufacturing (CMC) · Supplement 4AP
1992-03-18Labeling · Supplement 3AP
1986-12-01OriginalAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industry →GMP discipline →FDA drug shortages →FDA enforcement & recalls →

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →